Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men
Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men
The Spanner is being evaluated for use to manage voiding dysfunction and lower urinary tract
 symptoms in subjects to achieve bladder drainage in men unfit for other treatments.
Inclusion Criteria:

 -  Age > 45 years;

 -  In urinary retention and catheterized (indwelling or intermittent) for less than 180
 days;

 -  Documented diagnostic history (within 180 days of study) of detrusor contractility (>=
 15 cmH2O) confirmed via pressure-flow test;

 -  Negative Urinalysis on Visit 1;

 -  Not a candidate for pharmacologic, minimally invasive or surgical treatment of the
 prostate;

 -  Charlson Weighted Index of Comorbidity Score >= 1;

 -  Willing and able to sign the Informed Consent Form;

 -  Willing and able to complete the follow-up protocol requirements;

 -  Experiencing catheter-induced discomfort.

 Exclusion Criteria:

 -  Current use of a urinary catheter daily for greater than 180 consecutive days
 immediately preceding entering into the study;

 -  Positive Urinalysis on Visit 1;

 -  Current or recent (within the last 6 months) urinary tract disease including urethral
 stricture, bladder stones, and other significant urological conditions or surgery;

 -  Surgery altering the normal uro-genital anatomy or abnormal urethral anatomy that
 affect the function of the lower urinary tract;

 -  History of conditions associated with neurogenic bladder, including spinal cord
 injury, multiple sclerosis, or Parkinson's disease;

 -  Use of anticholinergic medication;

 -  Gross hematuria when catheter is removed on Visit 1;

 -  Known or suspected prostate cancer;

 -  Prior pelvic irradiation therapy;

 -  Prostatic urethral length < 4 cm or > 9 cm (combined length from the top proximal side
 of the bladder neck to the bottom distal side of the external sphincter);

 -  Intravesical enlargement of the median lobe of the prostate.